» Articles » PMID: 27826066

Plant Polyphenols As Natural Drugs for the Management of Down Syndrome and Related Disorders

Overview
Date 2016 Nov 10
PMID 27826066
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Polyphenols are secondary metabolites of plants largely found in fruits, vegetables, cereals and beverages, and therefore represent important constituents of the human diet. Increasing studies have demonstrated the potential beneficial effects of polyphenols on human health. Extensive reviews have discussed the protective effects of polyphenols against a series of diseases such as cancer, cardiovascular diseases, diabetes, and neurodegenerative disorders. Limited studies have investigated the potential therapeutic effects of these natural compounds on neurodevelopmental disorders associated with intellectual disability, such as Down syndrome (DS), for which mitochondrial dysfunctions and oxidative stress are hallmarks and contribute to the deleterious symptoms and cognitive decline. This review, starting from the structure, source, bioavailability and pharmacokinetics of relevant polyphenols, highlights recent studies on the effect and potential molecular mechanism(s) of action of the phenolic compounds epigallocatechin-3-gallate, resveratrol and hydroxytyrosol in restoring mitochondrial energy deficit and in reversing phenotypical alteration in DS. The clinical implications of plant polyphenol dietary supplements as therapeutic tools in managing DS and other intellectual disability-related diseases, is also discussed.

Citing Articles

Antioxidant activity of Micractinium sp. (Chlorophyta) extracts against HO induced oxidative stress in human breast adenocarcinoma cells.

Bulut O, Kose I, Sonmez C, Oktem H Sci Rep. 2024; 14(1):27593.

PMID: 39528524 PMC: 11555311. DOI: 10.1038/s41598-024-63960-6.


Obesity Control and Supplementary Nutraceuticals as Cofactors of Brain Plasticity in Multiple Sclerosis Populations.

Ciumarnean L, Sarb O, Draghici N, Salagean O, Milaciu M, Orasan O Int J Mol Sci. 2024; 25(20).

PMID: 39456690 PMC: 11507128. DOI: 10.3390/ijms252010909.


Network Pharmacology Identifies Intersection Genes of Apigenin and Naringenin in Down Syndrome as Potential Therapeutic Targets.

Amir M, Shafi S, Parveen S, Reshi A, Ahmad A Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204195 PMC: 11359399. DOI: 10.3390/ph17081090.


Brain Mitochondrial Bioenergetics in Genetic Neurodevelopmental Disorders: Focus on Down, Rett and Fragile X Syndromes.

Valenti D, Vacca R Int J Mol Sci. 2023; 24(15).

PMID: 37569863 PMC: 10419900. DOI: 10.3390/ijms241512488.


Blood tests and use of nutritional supplements in a cohort of Brazilian children with trisomy 21.

Miyasaki A, Radigonda J, Klein R, Moreira E J Pediatr (Rio J). 2023; 99(6):610-616.

PMID: 37353208 PMC: 10594004. DOI: 10.1016/j.jped.2023.05.009.